EUVIMEDEUVIMED entdecken
Fallbericht

Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sjögren’s syndrome: A case report

Mitsuru Watanabe iD, Yoichiro Haji, Mirai Hozumi, Yui Amari, Yukina Mizuno, Takanori Ito, Mizuki Kato, Masato Okada

Modern Rheumatology Case Reports · 19.06.2023 · 7 (2) · 475-479

DOI: 10.1093/mrcr/rxad020 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, online erschienen am 15.04.2023. Verfasst von Mitsuru Watanabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Daido Hospital, Nagoya city, Aichi, Japan. Hauptthemen laut MEDLINE: Kidney Diseases, Thrombocytopenia, Sjogren's Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TAFRO syndrome is a systemic inflammatory disease of unknown aetiology. It is characterised by thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly. Herein, we report the case of a 60-year-old male with TAFRO syndrome. A few weeks after the patient developed an intermittent fever, he presented to our hospital with diarrhoea, abdominal distension, and whole-body oedema (face, extremities, and abdomen). Autoantibody and lip biopsy findings supported the diagnosis of primary Sjögren’s syndrome. High-dose steroids and tocilizumab were used to treat his refractory thrombocytopenia and ascites. However, systemic inflammation and renal dysfunction did not improve, resulting in temporary haemodialysis. Eventually, combined B-cell immunomodulation therapy with rituximab and belimumab ameliorated the patient’s symptoms. About 16 weeks after discharge, the overall condition of the patient had improved. The TAFRO syndrome may be a severe manifestation of primary Sjögren’s syndrome. Considering the immunological context, combined B-cell immunomodulation therapy provides new insights into improving this life-threatening disease and enables rapid steroid tapering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney DiseasesThrombocytopeniaSjogren's SyndromeMaleRituximabEdemaHumansMiddle AgedAntibodies, Monoclonal, HumanizedCastleman Disease

Stichwörter der Autor:innen

TAFRO syndromebelimumaboedemaprimary Sjögren’s syndromerituximab

Substanzen

RituximabbelimumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Rheumatology, Daido Hospital, Nagoya city, Aichi, Japan.
  • Immuno-Rheumatology Center, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan.

ORCID-Profile: Mitsuru Watanabe

Zitieren

APA

Watanabe, M., Haji, Y., Hozumi, M., Amari, Y., Mizuno, Y., Ito, T., Kato, M., & Okada, M. (2023). Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sjögren’s syndrome: A case report. Modern Rheumatology Case Reports, 7(2), 475-479. https://doi.org/10.1093/mrcr/rxad020

Vancouver

Watanabe M, Haji Y, Hozumi M, Amari Y, Mizuno Y, Ito T, et al. Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sjögren’s syndrome: A case report. Modern Rheumatology Case Reports. 2023;7(2):475-479. doi:10.1093/mrcr/rxad020

BibTeX
@article{Watanabe2023,
  author = {Watanabe, Mitsuru and Haji, Yoichiro and Hozumi, Mirai and Amari, Yui and Mizuno, Yukina and Ito, Takanori and Kato, Mizuki and Okada, Masato},
  title = {Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sjögren’s syndrome: A case report},
  journal = {Modern Rheumatology Case Reports},
  year = {2023},
  volume = {7},
  number = {2},
  pages = {475--479},
  doi = {10.1093/mrcr/rxad020}
}
Kostenlos starten →